secwatch.observer — SEC 8-K summary
======================================

Issuer:     OPKO HEALTH, INC. (OPK)
CIK:        0000944809
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0000944809-23-000010
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OPKO Health Q4 2022 revenue drops to $185.4M; net loss $85.2M
-------------------------------------------------------------

- Consolidated revenue $185.4M vs $401.3M YoY; net loss $85.2M ($0.11/share) includes $49.1M non-cash charge on GeneDx investment.
- Diagnostics revenue $139.4M (down from $362.8M) due to COVID-19 testing decline; BioReference processed 0.1M PCR tests vs 2.7M.
- Pharmaceuticals revenue $37.9M (up from $35.3M) driven by RAYALDEE ($9.1M) and IP transfer ($8.1M); NGENLA sales underway in 15 countries.
- Operating loss $55.3M vs $63.1M; cash $153.2M as of Dec 31, 2022.
- BioReference implementing cost-cutting initiatives to return to profitability after COVID-19 testing decline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/944809/000094480923000010/0000944809-23-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/944809/000094480923000010/opk-20230223.htm
  HTML page:      https://secwatch.observer/filing/0000944809-23-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer